AC Immune Ltd Market Cap ($212.71 Million)
Market Cap & Net Worth: AC Immune Ltd (ACIU)
AC Immune Ltd market cap. AC Immune Ltd (NASDAQ:ACIU) has a market capitalization of $212.71 Million ($212.71 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16090 globally and #3847 in its home market, demonstrating a -9.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AC Immune Ltd's stock price $2.09 by its total outstanding shares 101773573 (101.77 Million). Also see AC Immune Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
AC Immune Ltd Market Cap History (2016–2026)
AC Immune Ltd market cap history from 2016 to 2026. Data shows change from $1.32 Billion to $212.71 Million (-18.05% CAGR). Check latest AC Immune Ltd stock price today for real-time trading data and today's change.
Index Memberships
AC Immune Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #437 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1583 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #221 of 263 |
Weight: AC Immune Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AC Immune Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AC Immune Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of AC Immune Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
89.44x
AC Immune Ltd's market cap is 89.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.32 Billion | $23.21 Million | -$7.10 Million | 56.91x | N/A |
| 2017 | $1.30 Billion | $20.25 Million | -$26.41 Million | 64.32x | N/A |
| 2018 | $961.76 Million | $7.19 Million | -$50.95 Million | 133.69x | N/A |
| 2019 | $867.11 Million | $110.46 Million | $45.44 Million | 7.85x | 19.08x |
| 2020 | $526.17 Million | $15.43 Million | -$61.92 Million | 34.10x | N/A |
| 2021 | $503.78 Million | $944.00K | -$73.00 Million | 533.66x | N/A |
| 2022 | $207.62 Million | $3.94 Million | -$70.75 Million | 52.76x | N/A |
| 2023 | $508.87 Million | $14.80 Million | -$54.23 Million | 34.38x | N/A |
| 2024 | $274.79 Million | $27.31 Million | -$50.92 Million | 10.06x | N/A |
| 2025 | $319.57 Million | $3.57 Million | -$70.45 Million | 89.44x | N/A |
Competitor Companies of ACIU by Market Capitalization
Companies near AC Immune Ltd in the global market cap rankings as of November 4, 2026. Also see total assets of AC Immune Ltd for a full breakdown of the balance sheet.
Key companies related to AC Immune Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of AC Immune Ltd (2016–2026)
Market capitalization of AC Immune Ltd from 2016 to today. Between 2016 and today, AC Immune Ltd's market cap moved from $1.32 Billion to $ 212.71 Million, with a yearly change of -18.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $212.71 Million | -33.44% |
| 2025 | $319.57 Million | +16.30% |
| 2024 | $274.79 Million | -46.00% |
| 2023 | $508.87 Million | +145.10% |
| 2022 | $207.62 Million | -58.79% |
| 2021 | $503.78 Million | -4.26% |
| 2020 | $526.17 Million | -39.32% |
| 2019 | $867.11 Million | -9.84% |
| 2018 | $961.76 Million | -26.17% |
| 2017 | $1.30 Billion | -1.39% |
| 2016 | $1.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of AC Immune Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $212.71 Million USD |
| MoneyControl | $212.71 Million USD |
| MarketWatch | $212.71 Million USD |
| marketcap.company | $212.71 Million USD |
| Reuters | $212.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more